ORIC · Company research
Oric Pharmaceuticals, Inc. (ORIC): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals stock closed at USD 12.35, volume 35.90 percent below average - ad-hoc-news.de | ORIC Pharmaceuticals stock closed at USD 12.35, volume 35.90 percent below average ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 17, 2026 | neutral | 0 | 0.6 |
| JPMorgan raises target for ORIC Pharmaceuticals stock to USD 26.00 - ad-hoc-news.de | JPMorgan raises target for ORIC Pharmaceuticals stock to USD 26.00 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 15, 2026 | neutral | 0 | 0.6 |
| Oric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% on Analyst Upgrade - MarketBeat | Oric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% on Analyst Upgrade MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock By Investing.com - Investing.com South Africa | Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock By Investing.com Investing.com South Africa | View source ↗ | Investing.com South Africa | Oct 13, 2026 | neutral | 0 | 0.6 |
| Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock - Investing.com | Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock Investing.com | View source ↗ | Investing.com | Oct 13, 2026 | neutral | 0 | 0.6 |
| ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits | ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance UK | ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.6% - Here's What Happened - MarketBeat | Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.6% - Here's What Happened MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| Cancer Research UK will fund early testing of a potential cancer treatment. - Stock Titan | Cancer Research UK will fund early testing of a potential cancer treatment. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Six new hires received options to buy shares and stock awards from ORIC Pharmaceuticals - Stock Titan | Six new hires received options to buy shares and stock awards from ORIC Pharmaceuticals Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18 - MarketBeat | Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18 MarketBeat | View source ↗ | MarketBeat | Sep 29, 2026 | neutral | 0 | 0.6 |
| $ORIC stock is up 13% today. Here's what we see in our data. - Quiver Quantitative | $ORIC stock is up 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 24, 2026 | neutral | 0 | 0.6 |
| ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha | ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 21, 2026 | neutral | 0 | 0.6 |
| ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha | ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout Seeking Alpha | View source ↗ | Seeking Alpha | Jun 12, 2026 | neutral | 0 | 0.6 |
| Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down - Fierce Biotech | Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down Fierce Biotech | View source ↗ | Fierce Biotech | Apr 1, 2026 | neutral | 0 | 0.6 |
| Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Investor's Business Daily | Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges Investor's Business Daily | View source ↗ | Investor's Business Daily | Apr 1, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.